 Connection
Anthony Elias to Soft Tissue Neoplasms
This is a "connection" page, showing publications Anthony Elias has written about Soft Tissue Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.721 |
|
|
|
-
Lopez JP, Gajdos C, Elias A. Trabectedin: novel insights in the treatment of advanced sarcoma. Curr Oncol Rep. 2014 Jun; 16(6):387.
Score: 0.434
-
Rosenbaum E, Chugh R, Ryan CW, Agulnik M, Milhem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi H, Elias AD, Read WL, Budd GT, Qin LX, Rodler ET, Hirman J, Weiden P, Bennett CM, Livingston PO, Ragupathi G, Hansen D, D'Angelo SP, Tap WD, Schwartz GK, Maki RG, Carvajal RD. A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2?and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. Eur J Cancer. 2022 11; 176:155-163.
Score: 0.194
-
Chawla SP, Van Tine BA, Pollack SM, Ganjoo KN, Elias AD, Riedel RF, Attia S, Choy E, Okuno SH, Agulnik M, von Mehren M, Livingston MB, Keedy VL, Verschraegen CF, Philip T, Bohac GC, Yurasov S, Yakovich A, Lu H, Chen M, Maki RG. Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. J Clin Oncol. 2022 04 20; 40(12):1291-1300.
Score: 0.178
-
Somaiah N, Van Tine BA, Wahlquist AE, Milhem MM, Hill EG, Garrett-Mayer E, Armeson KE, Schuetze SM, Meyer CF, Reuben DY, Elias AD, Read WL, Chawla SP, Kraft AS. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 03 15; 127(6):894-904.
Score: 0.170
-
Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am. 1995 Aug; 9(4):765-85.
Score: 0.118
-
Elias AD. Chemotherapy for soft-tissue sarcomas. Clin Orthop Relat Res. 1993 Apr; (289):94-105.
Score: 0.100
-
Southee AE, Kaplan WD, Jochelson MS, Gonin R, Dwyer JA, Antman KH, Elias AD. Gallium imaging in metastatic and recurrent soft-tissue sarcoma. J Nucl Med. 1992 Sep; 33(9):1594-9.
Score: 0.096
-
Elias AD. The clinical management of soft tissue sarcomas. Semin Oncol. 1992 Feb; 19(1 Suppl 1):19-25.
Score: 0.092
-
Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol. 1989 Sep; 7(9):1208-16.
Score: 0.078
-
Elias AD, Antman KH. Adjuvant chemotherapy for soft tissue sarcoma: an approach in search of an effective regimen. Semin Oncol. 1989 Aug; 16(4):305-11.
Score: 0.078
-
Antman KH, Elias AD. Chemotherapy of advanced soft-tissue sarcomas. Semin Surg Oncol. 1988; 4(1):53-8.
Score: 0.070
-
Elias AD, Antman KH. Adjuvant chemotherapy for soft-tissue sarcoma: a critical appraisal. Semin Surg Oncol. 1988; 4(1):59-65.
Score: 0.070
-
Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993 Jul; 11(7):1276-85.
Score: 0.025
-
Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989 Jan; 7(1):126-31.
Score: 0.019
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|